致残性与非致残性轻型缺血性卒中的急性期治疗:临床医生专家指导
该专家指导针对NIHSS≤5分的轻型急性缺血性卒中,基于症状致残性、再灌注资格和大血管闭塞提出场景化治疗框架。致残性症状4.5小时内优选静脉溶栓,非心源性非致残性事件标准用双联抗血小板;心源性不适合再灌注者48小时内早期抗凝似安全有益。
要点
- 轻型卒中占全部缺血性卒中过半,90天内高达30%出现残疾。
- 致残性症状4.5小时内优选静脉溶栓,非致残性非心源性用双抗。
- 心源性轻型卒中不适合再灌注时,48小时内启动抗凝似安全有益。
核心结论
- 轻型缺血性卒中并非良性病程,需根据致残性、再灌注资格和大血管闭塞进行场景化急性期决策。
研究设计与样本
- 专家指导类文章,基于随机试验、真实世界证据和国际指南构建场景化治疗框架。
主要发现
- 轻型卒中通常定义为NIHSS≤5分的急性缺血性卒中,占全部病例过半。
- 高达30%的患者在90天内出现残疾。
- 大血管闭塞的轻型卒中常规血管内治疗证据有限且存在争议。
关键数值与推荐
- 致残性症状在发病4.5小时内优选静脉溶栓。
- 非心源性、非致残性事件标准治疗为阿司匹林联合P2Y12抑制剂的双联抗血小板治疗。
- 心源性轻型卒中不适合再灌注时,48小时内早期抗凝似安全且有益。
临床怎么用
- 接诊轻型卒中需评估症状是否致残、再灌注资格及大血管闭塞状态以选择治疗。
- 对快速改善但仍致残的症状及再灌注后抗栓策略需个体化管理。
局限性
- 大血管闭塞的轻型卒中常规血管内治疗证据有限且存在争议。
- 需进一步研究以优化个体化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Minor ischemic strokes, usually defined as acute ischemic strokes with National Institutes of Health Stroke Scale score ≤5, account for over half of all cases and are often underestimated due to initially mild symptoms. Yet up to 30% of patients develop disability within 90 days, challenging the notion of a benign course. This guidance offers a pragmatic, scenario-based framework for acute minor ischemic stroke management, considering symptom severity (disabling versus nondisabling), eligibility for reperfusion, and presence of large vessel occlusion. Drawing from randomized trials, real-world evidence, and international guidelines, we examine therapeutic strategies, including dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor, anticoagulation, intravenous thrombolysis, and endovascular treatment. Intravenous thrombolysis is preferred for disabling symptoms within 4.5 hours of symptom onset, whereas dual antiplatelet therapy remains standard for noncardioembolic, nondisabling events. For cardioembolic minor ischemic stroke ineligible for reperfusion, early anticoagulation within 48 hours appears safe and beneficial. Evidence for routine endovascular treatment in minor ischemic stroke with large vessel occlusion remains limited and controversial. We also address management of rapidly improving yet disabling symptoms and postreperfusion antithrombotic strategies, emphasizing individualized care and the need for further research.
引用
- De Santis F, Foschi M, D'Anna L, et al. Acute Treatment of Disabling and Nondisabling Minor Ischemic Stroke: Expert Guidance for Clinicians. Stroke. 2025. PMID: 41376587. doi:10.1161/STROKEAHA.125.053504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。